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Common Abbreviations 
Ca2+ : Calcium  
CASQ2: Calsequestrin protein 
CPVT: Catecholaminergic Polymorphic Ventricular Tachycardia 
ECG: Electrocardiogram 
Het: Heterozygote 
Hom: Homozygote 
M-mode: Motion mode 
NSVT: Non-sustained ventricular tachycardia 
Null: Calsequestrin null  
PVC: Premature ventricular complex 
SERCA: Sarcoplasmic reticulum ATPase pump 
SR: Sarcoplasmic reticulum  
TG: Transgenic 
VT: Ventricular tachycardia 
WT: Wild-type 
2-D: Two dimension  
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ABSTRACT 
 Every year, approximately 40% of individuals in the United States die from heart 
failure. Pre-existing conditions such as diabetes and arrhythmia can lead to heart failure. 
Despite the number of individuals that develop heart failure, the underlying mechanisms 
are still not well understood. In order for cardiac contraction to occur, the myocardial 
cells uptake calcium from the cytosol into the sarcoplasmic reticulum (SR) via the 
sarcoplasmic reticulum ATPase pump (SERCA). With an increased SERCA pump, the 
cells can uptake and release more calcium, which may enhance cardiac fucntion. For this 
study, we hypothesized that (1) SERCA overexpression in the heart can be used to rescue 
the ventricular tachycardia caused by a depletion of calsquestrin, a buffer protein in the 
SR; (2) SERCA overexpression in the heart can be used to rescue cardiomyopathy that 
occurs during diabetes. Transgenic animal models were used for this study. In study 1, 
transgenic mice with SERCA overexpression were crossed with mice with calsquestrin 
depletion. In study 2, the SERCA overexpression mice along with their wild type 
littermates were made diabetic. Electrocardiographic recording was performed to detect 
arrhythmia in study 2. Cardiac function was measured by echocardiographic examination 
in both studies. Our data demonstrated that SERCA overexpression in the heart worsened 
ventricular arrhythmia and induced heart failure in mice with calsequestrin mutation. In 
addition, SERCA overexpression in the heart did not significantly improve cardiac 
function during diabetic cardiomyopathy. Overall this data suggests that SERCA 
overexpression in the heart does not rescue pre-existing conditions associated with 
arrhythmias and diabetic cardiomyopathy so individuals should be cautious when using 
SERCA gene therapy.  
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INTRODUCTION 
 The sarcoplasmic reticulum (SR) is an organelle that is present in many different 
cell types.1 The function of the SR in muscle cells is to sequester and release intracellular 
calcium (Ca2+). The SR contains the sarcoplasmic reticulum Ca-ATPase pump 
(SERCA). This SERCA pump has two functions. First, is to create muscle relaxation by 
up taking cytosolic calcium into the SR.2 Second, is to release calcium from the SR into 
the cytosol, which is needed for muscle contraction. When the SERCA pump does not 
function properly the levels of cytosolic calcium will increase, which can lead to 
apoptosis. SERCA pump dysfunction along with increased levels of cytosolic calcium 
have been shown to contribute to heart failure and diabetic cardiomyopathy.3 SERCA 
overexpression has been linked to enhanced contractile function so it is suggested that 
SERCA gene therapy could be used as a potential therapeutic option during cardiac 
failure.4 
 Heart failure is one of the leading causes of death in the United States. Heart 
failure can develop from a variety of conditions. Diabetes is one of the major conditions 
that predispose one to heart failure and ventricular arrhythmias have been associated with 
heart failure.5 Although both of these conditions have been linked to heart failure, the 
underlying mechanisms are not well understood.  
 The purpose of this study is to determine if increased SERCA expression in the 
heart can be used as a means to rescue arrhythmia and diabetic cardiomyoapthy, in order 
to prevent heart failure. For the proposed study, a well-characterized transgenic mouse 
model that overexpresses SERCA protein in the heart was used.2 The SERCA1a isoform 
in the heart was used in this study since there was a two fold increase in the total amount 
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of cardiac SERCA protein and SR Ca2+ uptake function.2 The hypothesis was that 
increased SERCA pump expression in the heart will increase SR Ca2+ reuptake and 
decrease the incidence of ventricular arrhythmia and the severity of diabetic 
cardiomyopathy. 
 
STUDY 1: SERCA AS A MEANS TO RESCUE ARRHYTHMIA  
In the United States, cardiovascular disease is one the leading cause of death and 
many individuals die from ventricular arrhythmia. Although the molecular mechanisms 
underlying these arrhythmias are not well understood, altered intracellular calcium 
handling in the heart has been implicated as a common pathway predisposing to 
ventricular tachycardia in acquired or congenital heart disease. Especially, 
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), which is a condition, 
that is inherited, can lead to sudden cardiac death that is triggered by physical or 
emotional stress.1 Catecholaminergic Polymorphic Ventricular Tachycardia can be 
detected by a normal baseline electrocardiogram (ECG) and polymorphic ventricular 
tachycardia was induced by catecholaminergic challenge. When Catecholaminergic 
Polymorphic Ventricular Tachycardia remains untreated, the mortality rate is high, 
reaching 30-35% by the age of 30.  
Catecholaminergic Polymorphic Ventricular Tachycardia has recently been linked 
to an autosomal recessive mutation in the calsequestrin (CASQ2) gene6. CASQ2 is 
located in SR and plays a prominent role in buffering free Ca2+ and allows an increase the 
amount of Ca2+ accumulated in the SR 7. In addition, the SERCA pump uptakes excess 
Ca2+, which was released during cardiac muscle contraction.8 The calcium that is taken 
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up by the SERCA pump is then buffered by CASQ2. Furthermore, when there is a 
mutation in the CASQ2 gene there is an alteration in calcium buffering capacity, which 
can lead to apoptosis and/or ventricular arrhythmia. Other studies have created a CASQ2 
null mouse model in which the CASQ2 gene is not expressed.9 Previous studies have 
shown that after catecholaminergic challenge mice with the CASQ2 mutation display 
ventricular arrhythmia and Catecholaminergic Polymorphic Ventricular Tachycardia.10   
The goal of the present study was to investigate if SERCA overexpression can be  
used as a means to rescue the effects of CASQ2 protein deficiency that causes ventricular 
arrhythmia leading to Catecholaminergic Polymorphic Ventricular Tachycardia. To test 
our hypothesis, we generated transgenic (TG) mice that have over-expression of the 
SERCA pump in the heart with TG mice that have CASQ2 depletion in the heart.  
 
MATERIAL AND METHODS 
 Generating TG mice 
 Dr. Knollman created the CASQ2 null TG mice model in which these mice have 
an absence of the CASQ2 buffering protein .9 The CASQ2 null mice were created by the 
deletion of the CASQ2 promoter and first exon. Dr. Periasamy developed a TG rodent 
model for SERCA overexpression in the heart. These two mice were then crossed in 
order to create the SERCA overexpression crossed with CASQ2 Null TG. When these 
two mice were crossed it resulted in offspring that were homozygote and heterozygote for 
the CASQ2 protein deficiency. In this study, five groups were used (Fig. 1). When the 
mice were 3-4 weeks old they were genotyped. The care of the mice conforms to the 
guide for Care and Use of laboratory animals published by the US national Institutes of 
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Health (NIH publication # 85-23, revised 1996)10. All procedures were approved by The 
Ohio State University Institutional Animal Care and Use Committee. 
 
 Fig 1.  For this study five different groups were used. WT: wildtype, SERCA: 
SERCA overexpression, Null: CASQ2 null, Het: Heterozygote (a cross between the 
SERCA overexpression and CASQ2 null resulting in decreased CASQ2 protein 
expression), Hom: Homozygote (a cross between the SERCA overexpression and 
CASQ2 null resulting in depletion of CASQ2 protein).  
 
 Echocardiographic monitoring 
 The equipment for the echocardiographic monitoring was available at the 
Biomedical Research Tower. The equipment used included an anesthesia chamber, 
anesthesia machine, and an ultrasound (Vevo 2100, Visual Sonics) with ultra-high linear 
frequency probes (ranging 9-70 MHz) which was suited to performing echocardiographic 
examinations on mice. Echocardiographic examination was performed (n=6) under 
general anesthesia (Fig 2). The mouse was placed in the anesthesia chamber with 3% 
SERCA +/+ 
CASQ2 +/-  
CASQ2 -/- 
 
SERCA +/+ 
CASQ2 -/- 
  
Null SERCA1a 
SERCA +/+ 
Het Hom 
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isoflurane and 100% oxygen. Once the mouse was under light anesthesia the mouse was 
transferred to a warmed platform, where the mouse was placed on its dorsal side and the 
anesthesia was maintained at ~1.5% isoflurane (inhalation via a mask). Gel was then 
applied to the hands and feet of the mice and the appendages were taped down to the 
platform to monitor the heart rate. After clipping of the hair the conducting gel was 
applied.  
 Diastole (i.e., cardiac relaxation) and systole (i.e., contraction of the heart) was 
assessed. Images acquired included: the motion mode (M-mode) of the left ventricle, 
two-dimensional (2-D) of the left ventricle, E and A wave, Pulmonary Artery velocity, 
and Aortic velocity. The M-mode image of the left ventricle was obtained by a cross 
section of the short axis of the left ventricle over time. The measurements for the short 
axis M-mode included the interventricular sepal dimension (IVS), left ventricular internal 
diameter (LVID), left ventricular posterior wall (LVPW) for both diastole and systole, 
and the calculated ejection fraction (EF) (EF = [(LVID end-diastolic – LVID end-
systolic)/ LVID end-diastolic]* 100%). The E and A wave measured the velocity of 
blood leaving the atrium and entering the left ventricle during the diastolic phase. The 
velocity of the E and A wave was measured along with timing of the contraction of the 
left ventricle, which includes aortic ejection time (AET), isovolumetric contraction time 
(IVCT) and isovolumetric relaxation time (IVRT).  The pulmonary artery velocity was 
obtained by the velocity of the blood going through the pulmonary artery. The doppler 
aortic velocity was obtained by measuring the velocity of blood going through the aortic 
arch and the measurements include the aortic ejection time (AET) and the left ventricular 
outflow tract (LVOT). Systolic function was measured using the M-mode of the left 
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ventricle and doppler views of the aorta and pulmonary artery. Once all of the images had 
been acquired, the isoflurane was turned off and the mouse was given time to awake on 
its own while on the table. Then the mouse was warmed for a few minutes before it is 
returned to the cage. 
 
Fig 2. The setup of the echocardiograph equipment depicting the probe and the 
anesthetized mouse on the heated platform. 
 
ECG monitoring and induction of arrhythmia 
 The equipment for the echocardiographic recording (ECG) was located at the 
Veterinary Medical Center. ECG recordings were performed for 30 min for all five-
mouse groups (n=5 per group) before and after catecholaminergic challenge. All of the 
necessary equipment was located in the Veterinary Medical Center, which included 
anesthesia induction chamber, anesthetic machine for small mammals and a physiologic 
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data acquisition system (MP 100, Biopac Systems) with a sampling rate of 2 kHz 6 (Fig 
3). The mouse was placed in the anesthesia chamber with 3% isoflurane in 100% oxygen. 
Once the mouse was anesthetized it was placed on a warmed heat pad with the dorsal side 
down. Then the leads were placed on the feet of the mouse with conducting gel. After a 
baseline recording of 10 minutes each mouse received one dose of isoproterenol (1.5 
mg/kg intraperitoneal injection). The recording was performed for 30 minutes, and then 
the isoflurane was turned off and the mouse was given time to wake up on its own. Once 
the mouse was awake it was placed back into the cage under a heat lamp.  
 
Fig 3. Electrocardiograph Biopac system used to obtain ECG recording in mice.  
 
Data and Statistical analysis  
 Signal average was obtained with software (AcqKnowledge, Biopack). The 
echocardiographic recording was analyzed for the presence of arrhythmias. The incidence 
of arrhythmias was analyzed by using a chi-squared test since there was a comparison 
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between two groups at a time. A one-way analysis of variance was used to analyze the 
heart rate and QT corrected. Statistical significance was evaluated at P<0.05 and all 
results were reported as mean ± SE.  
 
RESULTS 
Baseline heart rate (before isoproterenol injection) 
 The heart rate of the mice groups were calculated from the baseline recording of 
the ECG and then compared to one another. There was not a significant difference in the 
heart rate between the 5 groups of mice (Fig 4).  
  
Fig 4. The mean (± SE) heart rate of the five groups showed that there was not a 
significant difference between groups. Hom: Homozygote, Het: Heterozygote, Null: 
CASQ2 null, SERCA: SERCA overexpression, WT: Wild-type mice. 
 
 
 
0
100
200
300
400
500
600
700
WT SERCA Null Het Hom 
M
ea
n 
he
ar
t r
at
e 
(b
ea
ts
/m
in
)
 14 
Signal Average 
 The ECG machine recorded each heartbeat of the mice and the signal average was 
obtained with the use of AcqKnowledge software.  The signal average was an average of 
each heart beat over 60 seconds. A beat consisted of a P wave, QRS complex and a T 
wave. The P wave indicated atrial depolarization, which precedes atrial contraction.5 
QRS represented ventricular depolarization, which precedes ventricular contraction. The 
T wave represented ventricular repolarization (Fig 5).  
 
 Fig 5. Signal average (lead 1) depecting a P wave, QRS complex and a T wave. 
 
Baseline QT corrected 
 If the QT corrected (for heart rate, QTc) is prolonged then the mouse is pre-
exposed to ventricular arrhythmia. The QTc is a value that was calculated using the 
measured QT interval (ms) divided by 1000 and then divided by the cube root of the R-R 
interval (s). There was a significant difference in QT corrected between the Het mice and 
WT mice (P =0.013). There was not a significant difference between the other groups of 
mice (Fig 6).  
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Fig 6. There was a significant difference in QT corrected between the Het mice and WT 
mice. However there was not a significant difference between the other groups. * 
indicates a statistical difference from WT mice; P<0.05. Hom: Homozygote, Het: 
Heterozygote, Null: CASQ2 null, SERCA: SERCA overexpression, WT: Wild-type. 
 
Types of arrhythmia  
 Several types of arrhythmia were observed in the Hom mice and Het mice. There 
are two types of arrhythmia, simple and complex. Simple arrhythmia includes the 
premature ventricular complex (PVC) (Fig 7A) and fusion beats (Fig 7B). A PVC is a 
premature pulse beat.5 A fusion beat occurs on the ECG when there is a blending of a 
normal QRS with a PVC. Complex arrhythmia includes couplet (Fig 8A), triplet (Fig 
8B), bigeminey (Fig 8C), trigeminy, and non-sustained ventricular tachycardia (NSVT) 
(Fig 8D). A couplet is defined when there are two PVC’s concurrently, so a triplet is 
when there are three PVC’s concurrently. Bigeminey is defined as a repeated pattern of a 
normal sinus beat followed by a PVC. Non-sustained ventricular tachycardia is when 
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there are three or more PVCs in a row. Ventricular tachycardia (VT) is defined by 
consecutive PVC complexes where the heart beats faster, which last for more than 30 
seconds.  
 
Fig 7. Representative figure of the types of simple ventricular arrhythmia found in the 
Hom and Het mice. A is a premature ventricular complex. B is a figure of a fusion beat. 
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Fig 8. A representative figure of the types of complex ventricular arrhythmia displayed 
by Hom and Het mice. A is a couplet, B is a triplet, C is a bigeminey, D is non-sustained 
ventricular tachycardia.  
 
Baseline ECG arrhythmia 
 After analysis of the ECG recording, it was found that the Het mice had 
significantly more ventricular arrhythmias during the baseline recording (Fig 9). Het 
mice displayed more simple ventricular arrhythmia in baseline than the other groups. 
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Fig 9.  There was a significant increase in the cumulative number of simple ventricular 
arrhythmias in Het mice during the baseline ECG recordings. * represents statistical 
difference of P<0.05 from the other groups. N=5 per group 
 
After catecholaminergic challenge 
  After injection of isoproterenol, all the mice had increased heart rate (i.e., sinus 
tachycardia) validating our catecholaminergic challenge (Fig 10).  
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Fig 10.  The heart rate increased after catecholaminergic challenge in WT mice (A) and 
Hom mice (B). 
 
 
Arrhythmia after catecholaminergic challenge 
 After catecholaminergic challenge, the Hom and Het mice both displayed 
ventricular arrhythmia. The Hom and Het mice had significantly (P<0.001) more 
ventricular arrhythmia than the control groups (Fig 11). The Hom mice had significantly 
(P<0.001) more complex ventricular arrhythmia than the Het mice, including non-
sustained ventricular tachycardia (Fig 12). 
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Fig 11. The Hom and Het mice display significantly more cumulative simple and 
complex ventricular arrhythmia after catecholaminergic challenge than the control groups 
(i.e., WT, SERCA, Null). * represents a statistical difference of P<0.05 from the control 
group, + indicates a statistical difference from the Het (P<0.05). WT: wildtype, SERCA: 
SERCA overexpression, Null: CASQ2 null, Het: Heterozygote, Hom: Homozygote. 
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Fig 12. The Hom mice display significantly more cumulative complex ventricular 
arrhythmia after catecholaminergic challenge than the Het. * represents a statistical 
difference of P<0.05. WT: wildtype, SERCA: SERCA overexpression, Null: CASQ2 
null, Het: Heterozygote, Hom: Homozygote. 
 
 
Echocardiographic examination: systolic function  
 There were several mice that displayed heart failure in the Het and Hom groups: 
26.7% of the Het mice, and 14.3% of Hom mice. Heart failure was defined when the 
ejection fraction, a measure of systolic function, was considerably lower than the healthy 
mice (Fig 13). Our data showed that cardiac function in Het mice with heart failure were 
significantly different from control groups (Tables 1 and 2). 
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Fig 13. A: Representative short axis M-mode of the left ventricle. B: Representative E and A wave. IVS: Interventricular 
septal dimension, LVID: Left ventricular internal diameter, LVPW: left ventricular posterior wall dimension. 
 
Table 1. Systolic function parameters of 2D m-mode of the mice groups.  
 
 WT SERCA Null Het Het HF Hom  Hom HF 
 (n = 7) (n = 7) (n = 7) (n = 11) (n = 4) (n = 6) (n = 1) 
IVS;s (mm) 1.76 ± 0.15abd 1.76 ± 0.06b 1.34 ± 0.08c 1.42 ± 0.04cd 1.42 ± 0.06abcd 1.58 ± 0.06abcd 1.19 ± 0.0 
IVS;d (mm) 1.24 ± 0.08ac 1.36 ± 0.07bc  1.03 ± 0.07a  1.12 ± 0.03a  1.18 ± 0.08ab  1.09 ± 0.05a  0.99 ± 0.0 
LVPW;s (mm) 1.30 ± 0.07 1.38 ± 0.15 1.02 ± 0.06 1.01 ± 0.05 0.88 ± 0.07 1.29 ± 0.08 0.99 ± 0.0 
LVPW;d (mm) 0.95 ± 0.06ab 1.06 ± 0.11b 0.71 ± 0.02a 0.72 ± 0.04a 0.75 ± 0.06a 0.89 ± 0.09ab 0.91 ± 0.0 
LVID;s (mm) 2.13 ± 0.12af 2.74 ± 0.13b 2.35 ± 0.14abcf 2.09 ± 0.21bd 4.20 ± 0.17e 2.16 ± 0.14f  3.01 ± 0.0 
LVID;d (mm) 3.54 ± 0.13a 3.97 ± 0.15a 3.68 ± 0.17a  4.14 ± 0.12a 4.82 ± 0.28b 3.60 ± 0.15a 3.66 ± 0.0 
LV Vol;s (ul) 15.4 ± 2.09a 28.5 ± 3.30ac 19.9 ± 2.97a 33.2 ± 3.09c 79.0 ± 7.58b 16.0 ± 2.67a 35.4 ± 0.0 
LV Vol;d (ul) 52.8 ± 4.48a 69.8 ± 5.99ab 56.7 ± 6.91a 76.9 ± 5.56ab 110.1 ± 14.8b 55.1 ± 5.60a 56.5 ± 0.0 
LV Mass (mg) 155.9 ± 19.3a 211.1 ± 16.9b 115.2 ± 11.4a 152.5 ± 11.3a 208.8 ± 24.3bc 133.9 ± 10.0a 128.9 ±0.0 
LV Mass;c (mg) 124.7 ± 15.5a 168.9 ± 13.5b 92.1 ± 9.10a 122.0 ± 9.05a 167.1 ± 19.4bc 107.2 ± 8.03a 103.1 ± 0.0 
EF (%) 70.8 ± 3.58a 59.5 ± 2.44b 65.1 ± 2.82abc 57.5 ± 2.47bc 26.9 ± 3.90d 71.5 ± 2.71a  37.4 ± 0.0 
HR (b/min) 462.9 ± 19.5 480.6 ± 7.34 429.9 ± 14.2 440.5 ± 30.6 523.3 ± 44.7  460.6 ± 15.2 542.3 ± 0.0 
 
Data are mean ± SE. Different superscripts across rows indicate significant differences (P<0.05). 
HF: Heart failure, IVSs: Interventricular septal dimension-systole, IVS;d: Interventricular septal dimension-diastole, LVPW;s: left 
ventricular posterior wall dimension-systole, LVPW;d: left ventricular posterior wall dimension-diastole, LVID;s: left ventricular 
internal diameter-systole, LVID;d: Left ventricular internal diameter-diastole; LV Vol;s: Left ventricular volume-systole,  LV Vol;d: 
Left ventricular volume-diastole,  LV Mass;c: Left ventricular mass corrected, EF: ejection fraction, HR: heart rate. 
 
 
 24 
Table 2. Systolic function doppler parameters. 
 
 WT SERCA Null  Het Het HF Hom  Hom HF 
 (n = 7) (n = 7) (n = 7) (n = 11) (n = 4) (n = 6) (n = 1) 
Pulmonary         
PET/ET 0.27 ± 0.06ab  0.25 ± 0.02ab 0.20 ± 0.03b 0.26 ± 0.02ab 0.36 ± 0.06ab 0.33 ± 0.02a  
Aorta         
LVOT VTI VTI 
(mm) 
29.2 ± 1.96 25.5 ± 2.62 29.6 ± 2.34 26.1 ± 2.82 15.5 ± 2.32 24.8 ± 2.27 26.02 ± 0.00 
LVOT VTI Peak Vel 
(mm/s) 
-767.6 ± 47.9  -829.9 ± 77.6 -767.9 ± 71.9 -754.9 ± 80.3 -579.8 ± 67.9 -726.1 ± 71.6 -808.8 ± 0.00 
 
Data are mean ± SE. Different superscripts across rows indicate significant differences (P<0.05). 
HF: Heart failure, PET: Pulmonary ejection time, ET: Ejection time, LVOT VTI VTI: Left ventricular outflow tract length velocity 
time interval, LVOT VTI Peak Vel: Left ventricular outflow tract length peak velocity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Echocardiographic examination: diastolic function 
 
The diastolic parameters included the E and A wave, measured from the doppler 
image at the level of the mitral valve. The velocity of the blood entering the left ventricle 
during relaxation is measure by the E wave. The A wave was the velocity of the blood 
from the atrial kick, in which the atria contracts and blood flows into the left ventricle. 
There was a statistical difference between the Het HF group and the WT group for the 
E/A ratio (Table 3). 
 
Table 3. Diastolic function Doppler parameters 
 WT SERCA Null  Het Het HF Hom 
 (n = 7) (n = 7) (n = 7) (n = 11) (n = 4) (n = 6) 
MV E/A 2.01 ± 0.22ac 2.69 ± 0.20bc 1.60 ± 0.14a 1.73 ± 0.24a 1.01 ± 0.00a  2.15 ± 0.19ac 
MV Dec Time 
(ms) 
24.46 ± 2.15 21.7 ± 0.89  23.9 ± 1.76  22.8 ± 2.04  17.8 ± 0.00  16.3 ± 3.74 
MV Dec Acc 
(mm/s2) 
-33746 ± 
1833 
-39619 ± 
1525 
-30205 ± 
2969 
-37145 ± 
2351 
-59051 ± 
0.00  
-57669 ± 
18859 
 
Data are mean ± SE. Different superscripts across rows indicate significant differences 
(P<0.05). HF: Heart failure, MV E: Maximum velocity of the E wave, MV A: Maximum 
velocity of the A wave, MV Dec Time: Maximum velocity deceleration time, MV Dec 
Acc: Maximum velocity slope of deceleration.  
 
DISCUSSION 
 Our data demonstrated that: 1) QTc was prolonged in the Het mice compared to 
the WT mice. 2) More ventricular arrhythmias were present in the Het mice and Hom 
mice after catecholaminergic challenge, including non-sustained ventricular tachycardia. 
3) Some of the Het and Hom mice developed heart failure.  
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QTc  
 The QTc was significantly prolonged in the Het group vs WT group. A 
prolonged QT indicated a delay in ventricular depolarization. A prolonged QT indicates 
that the mouse is more prone to develop ventricular arrhythmia. Since the Het group has a 
prolonged QT then it was pre-exposed to ventricular arrhythmia. Indeed, at baseline and 
after catecholaminergic challenge, the Het mice displayed ventricular arrhythmia, 
including ventricular tachycardia. In humans, many individuals that display an elongated 
QT do develop Catecholaminergic Polymorphic Ventricular Tachycardia.11 
 
Arrhythmia in Het and Hom groups 
 There was a significant increase in the amount of ventricular arrhythmias present 
after catecholaminergic challenge in the Het mice and Hom mice than the control groups. 
The Het mice displayed more simple ventricular arrhythmia consisting of PVC and fusion 
beats where as the Hom mice had significantly more complex ventricular arrhythmias 
than the Het mice. These complex arrhythmias in the Hom mice mainly included non-
sustained ventricular tachycardia or ventricular tachycardia. Since these mice have a 
deficiency in the CASQ2 protein, which buffers calcium in the SR, and they have 
overactive SERCA pump, which was up taking more calcium into the heart, they were 
more likely to display arrhythmia.6 In conclusion, SERCA overexpression was unable to 
rescue Catecholaminergic Polymorphic Ventricular Tachycardia induced by CASQ2 
depletion.  
 
 
 27 
 
Heart failure in Het and Hom groups 
 A percentage of mice in the Hom group and Het group developed heart failure. 
The Het and Hom mice with heart failure had a significant decrease in the ejection 
fraction compared to the other groups. However, the Null mice do not develop heart 
failure. Only when the Null group is crossed with the SERCA overexpression group then 
we produced a heart failure genotype. Previous studies in humans have shown that the 
CASQ2 null gene mutation causes cardiac hypertrophy and heart failure along with an 
increased incidence of sudden death from stress-induced arrhythmia.12  
We concluded that the SERCA overexpression did not rescue ventricular 
arrhythmias in mice with CASQ2 depletion, and instead it created a phenotype that 
displays ventricular arrhythmias (including ventricular tachycardia) and heart failure. 
 
STUDY 2: SERCA AS A MEANS TO RESCUE DIABETIC CARDIOMYOPATHY 
 Diabetes is a major health problem that affects over 200 million individuals 
worldwide. Diabetes can lead to cardiomyopathy, independently of the presence of 
coronary artery disease. It has been shown that individuals with diabetes are more at risk 
for cardiac autonomic dysfunction.13 Many individuals that have diabetes are then 
predisposed for heart failure. Several studies have shown that diabetic cardiomyopathy is 
associated with a depletion of SERCA pump.3 
 Previously, in our lab it was shown that SERCA pump was down regulated during 
cardiomyopathy.3 The SERCA pump up takes cytosolic calcium and stores it for muscle 
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contraction. When the SERCA pump does not function properly this leads to a rise in 
cytosolic calcium levels, which is thought to occur during diabetes.  
 The purpose of this study is to determine if SERCA overexpression can decrease 
the effects of diabetes on cardiomyocytes and improve cardiomyopathy by reducing 
cytosolic calcium overload. For the proposed study, a well-characterized SERCA1a 
transgenic (TG) rodent model was used along with an insulin dependent rodent model. A 
few days after the streptozocin injection, the rodent had hyperglycemia that was sustained 
throughout the study and developed cardiac dysfunction, as shown previously in our 
laboratory. The hypothesis was that over expression of the SERCA pump will improve 
diabetic cardiomyopathy.  
 
MATERIAL AND METHODS 
Animal model of diabetic cardiomyopathy 
A well-characterized insulin dependent rodent model was used. The TG mice over 
expressing SERCA1a pump and their WT littermates (n = 6) were made diabetic by 
streptozotocin injection. A few days after streptozotocin injection, rodents displayed 
hyperglycemia which was sustained throughout the study.  Glucose, serum insulin 
concentrations and body weight were measured at baseline and every week for eight 
weeks. After the streptozotocin injection the blood glucose of both the WT and TG mice 
increased as expected, which indicated that all of the mice were diabetic. There were four 
groups of mice for this study 1) Wild-type diabetic (WT) 2) Wild-type control 3) SERCA 
over expression TG diabetic (TG) 4) SERCA overexpression TG control. 
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Generating the SERCA mouse model 
 A SERCA mouse model was established by Dr. Periasamy and was used for this 
study.2 The SERCA1a isoform was used since they have a two-fold increase in the total 
amount of cardiac SERCA protein and in calcium uptake. It has been shown that the 
SERCA1a form can substitute for the SERCA2a in the heart for both structure and 
function along with enhancing calcium transport and cardiac contraction.14, 15 
 
In vivo study 
  Echocardiographic examination was recorded at baseline and eight weeks after 
the induction of diabetes. Please refer to study 1 for a description of the methods. 
 
Statistical analysis 
 A 2-way repeated measure ANOVA was performed. The reason for using this test 
was because the same individual was used for the baseline measurement and the eight 
week measurement in order to determine the effects of diabetes on cardiac function in 
WT and SERCA over expression TG mice. All results were reported as mean ± SE.  
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RESULTS 
SERCA1a expression 
 The TG group did show expression of the SERCA1a (skeletal isoform) protein in 
cardiac tissue compared to the WT group (Fig 14 A). Also there was a prominent 
expression of the SERCA1a protein in both the healthy and diabetic TG mice (Fig 14 B).  
 
Fig 14. A) PCR analysis with tail samples from offspring of TG breeders, showing a 
distinct band of SERCA1a gene in the TG but not WT mice. B) Western blot of cardiac 
tissue from diabetic and littermate healthy WT and TG mice. CASQ2: Calsequestrin. 
Con: Control. Dx: Diabetic.  
 
 
 
 
A 
SERCA1a+/+ 
TG WT 
TG WT 
Con         Dx          Con       Dx 
SERCA 1a 
CASQ2 
SERCA 2a 
B 
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Echocardiographic examination 
 There was a statistical difference of the left ventricle mass corrected between the 
TG mice at eight weeks and the WT mice at eight weeks (Fig 15). The left ventricle mass 
was increased in the TG mice compared to the WT mice (Table 4). Heart rate of diabetic 
WT mice was significantly lower at eight weeks than baseline indicative of 
cardiomyopathy (Fig 16). There was not a statistical difference between the heart rate of 
the TG mice at baseline and at 8 weeks which could be due to a low sample volume or 
SERCA overexpression does decrease effects of cardiomyopathy. There was not a 
statistical difference regarding other systolic and diastolic parameters at baseline and 8 
weeks in both groups (Tables 5 and 6). 
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Fig. 15. A) Representative figure of the M-mode demonstrating systolic function. B) 
Representative figure of the E and A wave demonstrating diastolic function. IVS: 
Interventricular septal dimension, LVID: Left ventricular internal diameter, LVPW: left 
ventricular posterior wall dimension. 
 
 
 
 
 
 
 
A 
B 
A 
B 
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Table 4. Systolic function parameters in wildtype and transgenic mice at baseline and 8 
weeks following induction of diabetes. 
 
 Wildtype Transgenic 
 Baseline 8 Weeks Baseline 8 Weeks 
IVS;s (mm) 1.62 ± 0.06 1.62 ± 0.09 1.56 ± 0.13 1.71 ± 0.09 
IVS;d (mm) 1.16 ± 0.08 1.12 ± 0.08 1.19 ± 0.07 1.32 ± 0.09 
LVPW;s (mm) 1.19 ± 0.04 1.43 ± 0.24 1.41 ± 0.14 1.22 ± 0.08 
LVPW;d (mm) 0.78 ± 0.06 0.75 ± 0.06 1.22 ± 0.12* 0.98 ± 0.08* 
LVID;s (mm) 2.71 ± 0.08  2.69 ± 0.11 2.61 ± 0.29 2.92 ± 0.08 
LVID;d (mm) 4.07 ± 0.07 4.10 ± 0.13 3.74 ± 0.30 4.14 ± 0.09 
LV Vol;s (ul) 27.5 ± 1.92 27.1 ± 2.77 27.5 ± 5.28 32.5 ± 2.06 
 
LV Vol;d (ul) 73.1 ± 2.94 74.7 ± 5.44 62.4 ± 9.86 75.4 ± 3.97 
LV Mass;d (mg) 148.0 ± 10.6 160.1 ± 7.12 149.5 ± 7.41 152.0 ± 6.92 
LV Mass;c (mg) 127.4 ± 9.78 121.9 ± 7.29 
 
151.5 ± 13.5 164.9 ± 7.89* 
FS (%) 33.4 ± 0.96 34.5 ± 1.28  31.2 ± 4.22 29.1 ± 1.79 
EF (%) 62.6 ± 1.38 64.0 ± 1.74 58.6 ± 5.75 56.4 ± 2.64 
 
Data are mean ± SE for n= 6/group. P<0.05. 
* denotes different from WT for same time point. † denotes different from baseline.  
IVSs: Interventricular septal dimension-systole, IVS;d: Interventricular septal dimension-
diastole, LVPW;s: left ventricular posterior wall dimension-systole, LVPW;d: left 
ventricular posterior wall dimension-diastole, LVID;s: left ventricular internal diameter-
systole, LVID;d: Left ventricular internal diameter-diastole; LV Vol;s: Left ventricular 
volume-systole,  LV Vol;d: Left ventricular volume-diastole,  LV Mass;c: Left 
ventricular mass corrected, FS: fractional shortening, EF: ejection fraction, HR: heart 
rate, CO: cardiac output 
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Table 5. Diastolic function parameters in wildtype and transgenic mice at baseline and 8 
weeks following induction of diabetes. 
 
 Wildtype Transgenic 
 Baseline 8 Weeks Baseline 8 Weeks 
MV E/A 1.61 ± 0.29 1.44 ± 0.28 2.17 ± 0.19 2.22 ± 0.40 
MV Dec Time 
(ms) 
19.4 ± 2.77 25.0 ± 2.12 19.2 ± 1.89 20.9 ±0.72  
MV Dec Acc 
(mm/s2) 
-41351 ± 4415 -37094 ± 8119 -39583 ± 2191 -35360 ± 4092 
LV MPI 0.49 ± 0.06 0.42 ±0.03 0.62 ± 0.06 0.59 ± 0.07 
Data are mean ± SE for n= 6/group. P<0.05. * denotes different from WT for same time 
point. MV E: Maximum velocity of the E wave, MV A: Maximum velocity of the A 
wave, MV Dec Time: Maximum velocity deceleration time, MV Dec Acc: Maximum 
velocity slope of deceleration, LV MPI: Left ventricle myocardial performance index.  
 
 
Table 6. Systolic function doppler parameters in wildtype and transgenic mice at baseline 
and 8 weeks following induction of diabetes. 
 
 Wildtype Transgenic 
 Baseline 8 Weeks Baseline 8 Weeks 
Pulmonary      
PET/ET 0.23 ± 0.70 0.26 ± 0.43 0.25 ± 1.03 0.26 ± 0.47 
Aorta      
AET (ms) 48.6 ± 0.90 56.5 ± 3.16† 44.3 ± 2.14  52.0 ± 1.99† 
LVOT VTI VTI 
(mm) 
29.8 ± 1.87 28.6 ± 2.18 27.6 ± 2.18 26.5 ± 1.74 
LVOT VTI Peak 
Vel (mm/s) 
-887.7 ± 77.1 -776.5 ± 67.4 -899.8 ± 73.9 -733.8 ± 65.5 
 
Data are mean ± SE for n= 6/group. P<0.05, † denotes different from baseline.  
PET: Pulmonary ejection time, ET: Ejection time, AET: aortic ejection time, LVOT VTI 
VTI: Left ventricular outflow tract length velocity time interval, LVOT VTI Peak Vel: 
Left ventricular outflow tract length peak velocity.  
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Fig 16. There was a significant difference between the baseline and at 8 weeks in the WT 
mice heart rates. * denotes a significant difference from baseline (P<0.05).  
 
 
DISCUSSION 
 Our data demonstrated that: 1) There was not a difference in cardiac function 
between SERCA overexpression TG and WT healthy mice. 2) The WT mice had diabetic 
cardiomyopathy as evident by the decrease in heart rate of the WT mice eight weeks after 
diabetes. Diabetic TG mice did not display an improvement in cardiac function. 
 
SERCA pump  
 Other studies have found that the SERCA overexpression increases the amount of 
SR calcium intake, which increases the left ventricle contraction and relaxation.16, 4 
However; our study found that there was not a significant difference between the healthy 
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SERCA overexpression TG mice and the healthy WT mice. This could be due to the fact 
that the SERCA overexpression was only a 2 fold increase compared to other studies that 
use up to a 10 fold increase in SERCA overexpression.16 Previous studies have shown 
that the SERCA2a overexpression in mouse hearts did increase energetic costs of 
contraction and was detrimental to individuals with decreased energetics such as 
diabetes.17    Furthermore, in our animal model the mice genetically have SERCA 
overexpression whereas other studies have delivered SERCA gene via a catheter. All of 
these factors could account for the lack of an improvement in cardiac function of healthy 
and diabetic SERCA overexpression TG mice.  
 
Diabetic cardiomyopathy 
 WT mice displayed diabetic cardiomyopathy, as evident by a decrease in heart 
rate after 8 weeks of diabetes. Similarly, cardiac autonomic dysfunction has been 
reported during diabetes in humans.13 Autonomic dysfunction is a malfunction of the 
autonomic nervous system, specifically cardiac autonomic dysfunction. Autonomic 
dysfunction is created by the effects of diabetes that leads to weight loss and hypotension. 
The effects of autonomic dysfunction complicate underlying cardiovascular disease.18 In 
TG mice, there was not a statistical difference in the heart rate at 8 weeks compared to 
baseline which could be due to our relative small sample size or due to the fact that 
SERCA-overexpression improved diabetic cardiomyopathy.  
Previous studies have demonstrated that diabetes leads to altered calcium 
handling in the heart which can lead to cardiomyopathy and hypotension due to weight 
loss.13, 18 In addition, diabetes results in cardiomyopathy due to reduced contractility from 
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decreased Ca2+ handling by the SERCA pump.19 However, there was no major systolic or 
diastolic dysfunction in the WT, which could be due to the low dose of streptozotocin 
used to induce a mild form of diabetes. Other studies have shown that conditional 
increase in the SERCA2a protein to rodents with pre-existing cardiomyopathy had 
improved cardiac function.20, 21 Therefore, in our study; the lack of improvement in 
cardiac function in TG mice may be due to the difference in TG animal model. In 
addition, a low dose of streptozotocin was given to our mice so they have a mild case of 
diabetes compared to the other studies where the mice had a more severe form of 
cardiomyopathy.20, 21, 22 Finally, pressure volume loop measurement may offer a more 
sensitive tool to detect systolic and diastolic dysfunction compared to echocardiographic 
examination. Therefore, further in vitro studies are required to determine subtle changes 
in cardiac function in our TG mice with SERCA1a overexpression and diabetic 
cardiomyopathy. 
 
CONCLUSION 
 This study demonstrated that the increased expression of SERCA pump does not 
attenuate the incidence of arrhythmias or diabetic cardiomyopathy. SERCA 
overexpression did not rescue ventricular tachycardia in individuals with the CASQ2 
mutation and rather it induced heart failure. In regards to diabetes, SERCA only slightly 
improved diabetic cardiomyopathy that occurs during diabetes. These findings do not 
support the theory that SERCA gene therapy rescues heart failure and individuals should 
be cautious when promoting the use of this novel type of therapeutic intervention.  
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